Surmodics, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SRDX research report →
Companywww.surmodics.com
Surmodics, Inc. , together with its subsidiaries, provides surface modification technologies for intravascular medical devices, and chemical components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates in two segments, Medical Device and In Vitro Diagnostics (IVD).
- CEO
- Gary R. Maharaj
- IPO
- 1998
- Employees
- 389
- HQ
- Eden Prairie, MN, US
Price Chart
Valuation
- Market Cap
- $614.51M
- P/E
- -43.29
- P/S
- 7.02
- P/B
- 5.51
- EV/EBITDA
- -67.25
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 72.79%
- Op Margin
- -13.40%
- Net Margin
- -16.19%
- ROE
- -12.76%
- ROIC
- -7.75%
Growth & Income
- Revenue
- $126.08M · -4.91%
- Net Income
- $-11,542,000 · -651.43%
- EPS
- $-0.82 · -645.45%
- Op Income
- $-5,645,000
- FCF YoY
- -142.71%
Performance & Tape
- 52W High
- $43.00
- 52W Low
- $25.87
- 50D MA
- $30.68
- 200D MA
- $31.12
- Beta
- 1.39
- Avg Volume
- 435.96K
Get TickerSpark's AI analysis on SRDX
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 19, 25 | OLSON CHARLES W | sell | 20,101 |
| Nov 19, 25 | OLSON CHARLES W | sell | 800 |
| Nov 19, 25 | OLSON CHARLES W | sell | 18,337 |
| Nov 19, 25 | OLSON CHARLES W | sell | 10,653 |
| Nov 19, 25 | OLSON CHARLES W | sell | 13,579 |
| Nov 19, 25 | OLSON CHARLES W | sell | 17,883 |
| Nov 19, 25 | OLSON CHARLES W | sell | 19,243 |
| Nov 19, 25 | Manders John D. | sell | 1,862 |
| Nov 19, 25 | Manders John D. | sell | 4,810 |
| Nov 19, 25 | Manders John D. | sell | 8,155 |
Our SRDX Coverage
We haven't published any research on SRDX yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate SRDX Report →